• LAST PRICE
    6.4600
  • TODAY'S CHANGE (%)
    Trending Up0.1000 (1.5723%)
  • Bid / Lots
    6.4600/ 18
  • Ask / Lots
    6.4700/ 6
  • Open / Previous Close
    6.4000 / 6.3600
  • Day Range
    Low 6.1500
    High 6.5900
  • 52 Week Range
    Low 4.0300
    High 8.9600
  • Volume
    2,369,603
    average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 6.36
TimeVolumeBCRX
09:32 ET1110606.4499
09:34 ET1191986.5023
09:36 ET606966.485
09:38 ET440556.4687
09:39 ET466386.4696
09:41 ET1025376.31
09:43 ET485356.33
09:45 ET149946.3012
09:48 ET192926.31
09:50 ET170326.35
09:52 ET64806.35
09:54 ET364976.31
09:56 ET150006.23
09:57 ET286926.3
09:59 ET67066.305
10:01 ET147416.31
10:03 ET296156.305
10:06 ET296716.31
10:08 ET568946.29
10:10 ET1126946.275
10:12 ET224606.295
10:14 ET57956.315
10:15 ET216976.32
10:17 ET71186.325
10:19 ET61096.34
10:21 ET64936.3347
10:24 ET63896.295
10:26 ET112576.33
10:28 ET26406.315
10:30 ET67816.305
10:32 ET17686.3
10:33 ET211126.32
10:35 ET102876.31
10:37 ET86526.325
10:39 ET96516.305
10:42 ET37006.325
10:44 ET113066.335
10:46 ET202166.385
10:48 ET24836.385
10:50 ET69246.355
10:51 ET77156.37
10:53 ET43236.36
10:55 ET71866.3712
10:57 ET55096.355
11:00 ET36906.355
11:02 ET200476.335
11:04 ET170366.335
11:06 ET89366.34
11:08 ET102706.3005
11:09 ET140046.345
11:11 ET126236.3412
11:13 ET40926.3501
11:15 ET239936.38
11:18 ET69196.37
11:20 ET32576.385
11:22 ET106346.385
11:24 ET30806.385
11:26 ET42846.395
11:27 ET27006.395
11:29 ET27496.395
11:31 ET135556.395
11:33 ET26876.4
11:36 ET67906.42
11:38 ET40356.405
11:40 ET69996.39
11:42 ET50656.3825
11:44 ET32016.39
11:45 ET65486.4
11:47 ET38466.39
11:49 ET39406.405
11:51 ET94476.415
11:54 ET288496.45
11:56 ET25576.455
11:58 ET60966.475
12:00 ET99566.48
12:02 ET76956.4791
12:03 ET171726.48
12:05 ET84456.46
12:07 ET55596.46
12:09 ET24856.455
12:12 ET260676.455
12:14 ET12956.45
12:16 ET21256.455
12:18 ET273066.465
12:20 ET53556.475
12:21 ET32476.485
12:23 ET27786.475
12:25 ET29506.475
12:27 ET33946.465
12:30 ET2615416.525
12:32 ET212926.505
12:34 ET321166.51
12:36 ET618066.505
12:38 ET110806.475
12:39 ET56516.475
12:41 ET124876.4899
12:43 ET177956.475
12:45 ET716686.46
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesBCRX
BioCryst Pharmaceuticals Inc
1.3B
-6.1x
---
United StatesMDXG
MiMedx Group Inc
1.2B
21.2x
---
United StatesKNSA
Kiniksa Pharmaceuticals Ltd
1.4B
236.2x
---
United StatesVCYT
Veracyte Inc
1.8B
-25.5x
---
United StatesDVAX
Dynavax Technologies Corp
1.4B
222.5x
---
United StatesGLPG
Galapagos NV
1.9B
58.4x
---
As of 2024-05-16

Company Information

BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on improving the lives of people living with complement-mediated and other rare diseases. The Company leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older.

Contact Information

Headquarters
4505 Emperor Blvd Ste 200DURHAM, NC, United States 27703-8457
Phone
919-859-1302
Fax
919-859-1314

Executives

Independent Chairman of the Board
Nancy Hutson
Chief Executive Officer, Director
Jon Stonehouse
Chief Financial Officer
Anthony Doyle
Chief Commercial Officer
Charles Gayer
Chief Research & Development Officer
Helen Thackray

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$1.3B
Revenue (TTM)
$355.4M
Shares Outstanding
206.4M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.88
EPS
$-1.07
Book Value
$-2.21
P/E Ratio
-6.1x
Price/Sales (TTM)
3.7
Price/Cash Flow (TTM)
---
Operating Margin
-33.43%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.